Business Context and Reporting Period
This Form 8-K was filed by EyeGate Pharmaceuticals, Inc. on May 24, 2016. The report discloses the entry into a material definitive agreement to establish an at-the-market equity offering program. Note: The request metadata references "Kiora Pharmaceuticals Inc," but the filing text explicitly identifies the registrant as "EyeGate Pharmaceuticals, Inc."
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. It is a current report focused solely on a corporate action regarding equity issuance.
Material Changes and Agreements
- Agreement Type: At The Market Offering Agreement.
- Counterparty: H.C. Wainwright & Co., LLC.
- Shares Authorized: Up to 1,319,289 shares of common stock (par value $0.01 per share).
- Commission Rate: Fixed at 3.0% of gross proceeds per share sold.
- Sale Method: Sales may be made via ordinary brokers' transactions on the NASDAQ Capital Market at prevailing market prices.
- Flexibility: The Company has no obligation to sell any shares and may suspend or terminate the agreement at any time.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, operational outlook, or specific risk factors beyond standard securities law disclaimers. The Company noted that the agreement is incorporated by reference into a previously filed Form S-3 Registration Statement (File No. 333-210557). No unusual items or contingencies were disclosed in this specific report.
Investor Verification Checklist
- Verify the current share count and the percentage of total outstanding shares represented by the 1,319,289 authorized shares.
- Review the referenced Form S-3 Registration Statement (File No. 333-210557) for broader capitalization details.
- Monitor future filings to determine if and when shares are actually sold under this program.
- Confirm the Company's current cash position to assess the necessity of this equity program.